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doi:10.1016/j.numecd.2009.07.001Abstract Background and aim: Platelet nitric oxide (NO) synthesis is compromised in
patients with acute coronary syndrome (ACS), and platelet NO availability may be critically
relevant in determining the extent of thrombosis in ACS patients. It has been demonstrated
that an impaired responsiveness to the antiaggregatory effects of NO may affect platelet
dysfunction in diabetic patients with ACS. Since NO availability may be genetically deter-
mined, we have investigated the role of endothelial nitric oxide synthase (eNOS) gene in influ-
encing platelet aggregability in relation to the presence (nZ 247) or absence (nZ 883) of
type 2 diabetes in ACS patients.
Methods and results: We have genotyped 1130 consecutive high risk ACS patients on dual anti-
platelet therapy, previously investigated in relation to platelet function. eNOS 4a allele
frequency was significantly higher in diabetic vs. non-diabetic patients (pZ 0.02). In non-dia-
betic patients the eNOS 4a allele significantly modulated platelet aggregability in response to
arachidonic acid (AA), but not to collagen and adenosine diphosphate (ADP) stimulus, after
Bonferroni correction for multiple testing. After adjustment for age, gender, smoking habit,
hypertension and ejection fraction 40%, the eNOS 4a allele remained significantly and inde-
pendently associated with platelet aggregability in response to AA stimulus [b (SE)Z 0.17
(0.07), pZ 0.01]. When platelet aggregation values were considered according to the pres-
ence or absence of high residual platelet reactivity (RPR) eNOS 4a, but not 786C and 894T,is study was supported in part by the Genopolis government FIRB project, and in part by grant to the
Risparmio Florence, Italy.
of Medical and Surgical Critical Care, University of Florence, Viale Morgagni 85, 50134 Florence, Italy.
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12 C. Fatini et al.allele was significantly associated with RPR by AA stimulus. The haplotype reconstruction anal-
ysis for eNOS gene showed that the 786C/894G/4a and 786C/894G/4b haplotypes signifi-
cantly influenced platelet aggregation after AA stimulus.
Conclusions: Our study indicates that eNOS 4a allele, may be a determinant of higher platelet
aggregability and residual platelet reactivity in non-diabetic ACS patients.
ª 2009 Elsevier B.V. All rights reserved.Introduction
Platelet nitric oxide (NO) synthesis is compromised in
patients with acute coronary syndrome (ACS) [1], and
platelet NO availability may be critically relevant in
determining the extent of thrombosis in ACS patients,
possibly related to an abnormal platelet activation. An in
vivo platelet activation may be related not only to
a decreased NO production, but also to increased formation
of reactive oxygen species (ROS) [2], as observed in dia-
betes. Recently it has been demonstrated that an impaired
responsiveness to the antiaggregatory effects of NO, prob-
ably related to increased NO clearance by O2
, may affect
platelet dysfunction in diabetic patients with acute coro-
nary syndrome (ACS) [3].
NO is a physiologically relevant inhibitor of platelet
aggregation, and a reduction in NO bioavailability may
represent a contributing factor in affecting platelet
phenotype in diabetes. Platelets have the capacity to
synthesize and release bioactive NO, and the role of
platelet-derived NO has been receiving increasing atten-
tion. NO is released simultaneously with platelet aggrega-
tion and may regulate platelet recruitment [4]. NO release
from activated human platelets inhibits platelet recruit-
ment, thus possibly limiting progression of intra-arterial
thrombosis [4]. An in vivo study provided evidence that
systemic infusion of the nitric oxide synthase (NOS) inhib-
itor L-N-mono-methyl-arginine citrate (L-NMMA) enhances
platelet reactivity to various agonists [1], supporting the
clinical relevance of platelet-derived NO. Data from
experimental studies showed controversial findings con-
cerning the existence of platelet NOS. Both constitutive
and inducible NO synthases have been identified in human
platelets [5], and data from an experimental study per-
formed on eNOS deficient mice demonstrated that stimu-
lated platelets were found to lack stimulation-dependent
NO release [6]. Nevertheless, recently it has been demon-
strated that human and mouse platelets do not express
eNOS/iNOS [7].
NO availability may be genetically determined, and
there is documented evidence linking reduction in NO
production, induced by eNOS gene polymorphisms, with
endothelial dysfunction. eNOS gene (7q35eq36) exhibits
several polymorphisms, some of which appear to be related
with the variability in NO plasma levels: a substitution of
guanine to thymine at nucleotide 894 in exon 7 of the eNOS
gene (894G > T polymorphism) is associated with reduced
basal NO production [8]; the rare C allele of the 786T > C
polymorphism in the 50-flanking region of the gene results in
a significant reduction in eNOS promoter activity [9]; and,
finally, a 27-base pair (bp) variable tandem repeats poly-
morphism in intron 4 (also called eNOS 4a4b) has beenassociated with variations in NO, nitrite and nitrate plasma
levels [10]. Recently, it has been demonstrated a functional
role for the eNOS 4a4b polymorphism: subjects carrying the
4a4a genotype have lower NO-producing activity comparing
to subjects carrying the wild-type allele, even if higher
eNOS mRNA levels were observed [11].
We previously demonstrated that the eNOS gene and in
particular the 4a/4b polymorphism represents a predispos-
ing condition to ACS [12], possibly related to endothelial
dysfunction. Thus, it would be intriguing to investigate the
role of eNOS gene in influencing the platelet aggregation,
as a marker of platelet dysfunction, in a large cohort of
previously investigated ACS patients on dual antiplatelet




This analysis includes 1130 consecutive patients admitted
to the Department of Medical and Surgical Critical Care,
Coronary Care Units of the Azienda Ospedaliero-Uni-
versitaria Careggi, University of Florence with the diagnosis
of acute coronary syndromes (ACS), previously investigated
[13e15]. Two hundred and forty-seven out of 1130 patients
analyzed were diagnosed with type 2 diabetes. Acute
myocardial infarction was diagnosed on the basis of an
increase in creatine kinase MB isoenzyme to at least twice
the upper normal limits (3.6 ng/ml), and/or elevated
cardiac troponin I (cTnI) (>0.15 ng/ml) levels with at least
one of the following: acute onset of prolonged (20 min)
typical ischemic chest pain; ST-segment elevation of at
least 1 mm in two or more contiguous electrocardiographic
leads; ST-depression of 0.5 mm, 0.08 s after the J point in
2 contiguous leads or T waves inversion >1 mm in leads
with predominant R waves. All patients underwent coro-
nary angiography performed by the Judkins’ technique and
PCI. Patients were considered to have hypertension if they
had been diagnosed as hypertensive according to the
European Society of Hypertension/European Society of
Cardiology guidelines or were taking anti-hypertensive
drugs. Dyslipidemia was defined according to the Third
report of the National Cholesterol Education Program, and
diabetes according to the American Diabetes Association.
The exclusion criteria included history of bleeding
diathesis, platelet count 100,000/mm3 hematocrit 30%
and serum creatinine 4.0 mg/dl. All patients received
a loading dose of 600 mg of clopidogrel orally before the
procedure and of 500 mg of ASA intravenously, followed by
75 mg of clopidogrel and 100e325 mg of ASA daily.
Unfractioned heparin 70 IU/Kg was used during the
Platelet aggregability, eNOS locus and diabetes 13procedure as an anticoagulant. The use of glycoprotein
(Gp) IIb/IIIa inhibitors was at the discretion of the operating
surgeon. For patients receiving the IIb/IIIa inhibitor in the
catheterization laboratory, blood samples were obtained
after 6 days. Informed written consent was obtained from
all patients, and the study was approved by the local
Ethical Review Board.
Blood sampling and assessment of platelet
aggregation on platelet-rich plasma
Venous blood samples were taken from each patient at
15e24 h after PCI intervention in tubes containing 3.2%
trisodium citrate.
Platelet aggregation was assessed using platelet-rich
plasma (PRP) by the turbimetric method in a four-channel
aggregometer (APACT 4, Labor Biomedical Technologies
GmbH, Ahrensburg, Germany) as previously reported [16].
Platelet agonists included 10 mM ADP, 2 mg/mL collagen,
and 1mM arachidonic acid (AA).
Antiplatelet response
For antiplatelet response, the following definitions were
used:
1. Residual platelet reactivity (RPR) evaluated by 10 mM
ADP-induced platelet aggregation (ADP-RPR)Z 10 mM
ADP-induced platelet aggregation 70% [13].
2. Residual platelet reactivity (RPR) evaluated by 1 mM AA-
induced platelet aggregation (AA-RPR)Z AA-induced
platelet aggregation 20% [17].
3. Residual platelet reactivity (RPR) evaluated by 2 mg/mL
collagen-induced platelet aggregation (collagen-RPR)
Z 2 mg/mL collagen-induced platelet aggregation
56% (90 percentile).Analysis of eNOSL786T> C, 894G> T and 4a/4b
polymorphisms
Genomic DNA was isolated from whole blood by using the
FlexiGeneDNA kit (QIAGEN, Germany).
eNOS786T > C (rs2070744) and 894G > T (rs1799983)
polymorphisms were evaluated through electronic micro-
chip technology (NanoChip Molecular Biology Workstation;
10  10 array NanoChip cartridge; Nanogen, San Diego, CA,
USA), by using the Universal Reporting System, as previ-
ously described [18]. The amplification of the sequence
containing each SNP has been performed through PCR
reaction in a MJ thermocycler (MJ research, Waltham, MA,
USA). Primers used in the amplification process and Cy3 and
Cy5-labelled universal reporter oligonucleotides are
reported in Appendix 1.
The eNOS 4a/4b polymorphism was analyzed as previ-
ously described [12].
Statistical analysis
Statistical analysis was performed by using the SPSS
(Statistical Package for Social Sciences, Chicago, USA)software for Windows (Version 11.5). The c2-test was used
to test for deviation of genotype distribution from Hardye
Weinberg equilibrium for all polymorphisms analyzed.
Genotype and allele frequencies were compared between
groups by using the c2-test. Categorical variables were
expressed as frequencies and percentages. Unless other-
wise indicated, data are given as median values and range.
Log-transformed values for all circulating parameters were
used in the analysis, and back transformed for data
presentation. General linear model was carried out to
investigate the possible relationship between eNOS poly-
morphisms and maximal platelet aggregation.
To test the association between platelet function and
the eNOS polymorphisms we performed the univariate
linear regression analysis with 2 mg/mL collagen or 10 mM
ADP or log(AA) platelet aggregation as dependent variable
and eNOS polymorphisms as independent variables. Age,
gender, hypertension, smoking habit and ejection fraction
40%, which were previously demonstrated to influence
platelet aggregation [19], were included in the multivariate
linear regression analysis as independent variables. The
Bonferroni correction was used for multiple testing (the 3
candidate polymorphisms were treated as 3 independent
statistical tests) by multiplying the nominal p-value of each
test by the number of tests conducted. To test the influ-
ence of eNOS polymorphisms on the presence or absence of
residual platelet reactivity (RPR), we performed the logistic
regression analysis.
In genotyping the eNOS 4a/4b polymorphism we found
the presence of two rarer alleles (c and d alleles), which
have been previously described in ACS population, in six
patients [20]. In order to avoid confounding effects on
statistical analysis, we excluded these patients from the
analysis concerning 4a/4b polymorphism. We performed
the analysis under a dominant genetic model of inheri-
tance. The dominant genetic model compares individuals
with one or more polymorphic alleles with a baseline group
with no polymorphic alleles (e.g. eNOS 4a4a þ 4a4b vs.
4b4b). The recessive genetic model compares the 4a4a
genotype with the combined 4a4b þ 4b4b genotypes, which
form the baseline group. The additive genetic model
assumes that there is a linear gradient in risk between the
4a4a, 4a4b and 4b4b genotypes (4b4b genotype baseline).
This is equivalent to a comparison of the 4a allele vs. the 4b
allele (baseline). A p-value <0.05 was considered to indi-
cate statistical significance. Haplotype reconstruction and
frequency estimation were performed using the R (http://
www.r-project.org) package haplo.stats by expectatione
maximization strategy (EM algorithm) [21]. The haplo.stats
package was also used to identify statistically significant
associations between haplotypes and disease risks by
means of generalized linear models.
Results
Demographic and clinical characteristics of patients are
reported in Table 1.
All three eNOS polymorphisms analyzed were in Hardye
Weinberg equilibrium. As concerns the eNOS 4a4b poly-
morphism, we excluded from the analysis 4 patients
carrying rarer alleles (i.e. c and d) previously identified
[20], in order to avoid confounding effects.
Table 1 Demographic and clinical characteristics of ACS





nZ 247 nZ 883
Age (years)a 64 (39e90) 68 (27e94)
Gender (M/F) 171/76 668/215
Hypertension, n (%) 174 (70.4) 556 (63.0)
Smoking habit, n (%) 76 (30.8) 377 (42.7)
Dyslipidemia, n (%) 150 (60.7) 477 (54.0)
BMI>25 Kg/m2, n (%) 30 (12) 124 (14)
Renal failure, n (%) 64 (25.9) 216 (24.5)
Ejection fraction (EF)
40%, n (%)
87 (35.2) 225 (25.5)
Family history of CAD,
n (%)
20 (8.1) 75 (8.5)
Previous AMI, n (%) 25 (10) 79 (8.9)
Multivessel disease, n (%) 116 (46.9) 291 (32.9)
Bifurcation lesions, n (%) 96 (38.8) 309 (35)
Drugs
b-blockers, n (%) 143 (58.9) 547 (62.0)
Ca-antagonists, n (%) 43 (17.4) 145 (16.4)
Statins, n (%) 209 (84.6) 745 (84.3)
ACE-inhibitors, n (%) 206 (83.4) 725 (82.1)
Nitrates, n (%) 62 (25.1) 187 (21.2)
Diuretics, n (%) 65 (26.3) 181 (20.5)
Proton pump inhibitors,
n (%)
232 (93.9) 825 (93.4)
a Median (range).
14 C. Fatini et al.Genotype distribution and allele frequency of the eNOS
polymorphisms are reported in Table 2. As concerns the 4a/
4b polymorphism, a significant difference in genotype
distribution and allele frequency between diabetic andTable 2 Genotype distribution and allele frequency of
eNOS 786T > C, 894G > T and 4a/4b polymorphisms in ACS
patients with and without diabetes.






nZ 247 nZ 883
eNOS 786TT 75 (30.4) 257 (29.1)
786TC 127 (51.4) 452 (51.2)
786CC 45 (18.2) 174 (19.7) 0.8
786C 0.44 0.45 0.6
eNOS 894GG 111 (44.9) 361 (40.9)
894GT 108 (43.7) 404 (45.8)
894TT 28 (11.3) 118 (13.4) 0.5
894T 0.33 0.36 0.2
eNOS 4b/4ba 161 (65.2) 621 (70.3)
4a/4b 72 (29.1) 242 (27.4)
4a/4a 13 (5.3) 17 (1.9) 0.01
4a 0.20 0.16 0.02
a 4 patients heterozygous for rarer alleles (i.e. c and d allele)
are not included in the analysis.non-diabetic patients (pZ 0.01 and pZ 0.02, respec-
tively) was found.
Platelet phenotype in diabetic and non-diabetic
patients
Maximal platelet aggregation values [geometric mean (95%
CI)] were significantly higher in diabetic in comparison to
non-diabetic patients, in response to collagen: [37.8 (34.5e
41.07) vs. 30.4 (28.7e32.1), p < 0.000], ADP: [54.7 (51.8e
57.6) vs. 46.8 (45.3e48.3), p < 0.0001] and AA stimuli:
[26.4 (23.3e29.4) vs. 19.8 (19.2e21.4), p < 0.0001].
eNOS L786T> C, 894G> T and 4a/4b
polymorphism and platelet phenotype in diabetic
and non-diabetic patients
In diabetic patients carrying eNOS rare alleles for all poly-
morphisms analyzed, the difference in platelet aggregation
values was not statistically significant in comparison to
wild-type allele carriers, after AA, collagen and ADP stimuli
(p > 0.05). On the contrary, we found significantly higher
platelet aggregation values in response to collagen and AA,
but not ADP stimulus, in non-diabetic patients carrying the
eNOS 4a rare allele. Moreover, a significantly higher
platelet aggregation value in response to collagen, but not
to AA and ADP stimuli, was observed in non-diabetic
patients carrying the eNOS 786C allele. The eNOS 894
G > T polymorphism did not influence platelet aggregation
in response to all stimuli analyzed in non-diabetic patients.
In non-diabetic patients, the univariate linear regression
analysis model with collagen, ADP and AA-induced platelet
aggregation values analyzed as continuous variables, was
performed according to dominant, recessive and additive
model of inheritance. We observed a significant association
between eNOS 4a allele and both AA and collagen-induced
platelet aggregation and between eNOS 786C allele and
collagen-induced platelet aggregation under a dominant, but
not recessive and additive model of inheritance. After Bon-
ferroni correction for multiple testing, only eNOS 4a allele
remained significantly associated with AA-induced platelet
aggregation. The eNOS 894T allele did not affect platelet
aggregation under all genetic models investigated (Table 3).
At the multivariate linear regression analysis model with
AA-induced platelet aggregation as dependent variable,
and age, gender, smoking habit, hypertension and ejection
fraction 40% as independent variables, eNOS 4a signifi-
cantly and independently influenced platelet aggregation in
response to AA stimulus (Table 3).
When platelet aggregation values were considered
according to the presence or absence of high residual
platelet reactivity (RPR), at logistic regression analysis,
eNOS 4a, but not 786C and 894T, allele was significantly
and independently associated with RPR by AA, but not by
collagen and ADP, under the dominant model of inheritance
(Table 4).
The haplotype reconstruction analysis for eNOS gene
showed that the 786C/894G/4a and 786C/894G/4b haplo-
types significantly and independently influenced platelet
aggregation after AA, but not ADP and collagen, stimulus
(Appendix 2).
Table 3 Univariate and multivariate linear regression analysis with 1 mM AA, 2 mg/mL Collagen, and 10 mM ADP platelet
aggregation values analyzed as continuous variables in non-diabetic patients, according to genetic models of inheritance.
log (AA) Collagen ADP
b (SE) p b (SE) p b (SE) p
Univariate linear regression analysis (Dominant Model)
eNOS 786C 0.12 (0.06) 0.06 4.18 (1.89) 0.03a 2.98 (1.69) 0.08
eNOS 894T 0.05 (0.06) 0.4 0.32 (1.76) 0.9 1.52 (1.57) 0.3
eNOS 4a 0.18 (0.06) 0.006a 3.85 (1.87) 0.04a 2.40 (1.69) 0.2
Univariate linear regression analysis (Recessive Model)
eNOS 786CC 0.03 (0.07) 0.7 2.20 (2.16) 0.3 0.22 (1.95) 0.9
eNOS 894TT 0.03 (0.09) 0.7 0.88 (2.53) 0.7 1.90 (2.29) 0.4
eNOS 4a4a 0.05 (0.23) 0.8 7.50 (6.40) 0.2 8.92 (5.80) 0.1
Univariate linear regression analysis (Additive Model)
eNOS 786CC vs. TT 0.11 (0.09) 0.2 4.74 (2.55) 0.06 2.28 (2.32) 0.3
eNOS 894TT vs. GG 0.06 (0.10) 0.6 0.96 (2.86) 0.7 0.75 (2.47) 0.8
eNOS 4a4a vs. 4b4b 0.005 (0.22) 0.9 6.25 (6.40) 0.3 8.05 (5.80) 0.2
Multivariate linear regression analysis (Dominant Model)
eNOS 4a 0.17 (0.07) 0.01 e e e e
Age 0.01 (0.003) <0.0001 e e e e
Gender 0.05 (0.07) 0.5 e e e e
Smoking habit 0.09 (0.06) 0.2 e e e e
Hypertension 0.12 (0.06) 0.05 e e e e
Ejection fraction40% 0.06 (0.07) 0.4 e e e e
a Bonferroni correction for multiple testing by multiplying the nominal p-value of each test by 3 (i.e. the number of tests conducted):
eNOS 4a and log (AA) pZ 0.02; eNOS 4a and collagen pZ 0.12; eNOS 786C and collagen pZ 0.09.
Platelet aggregability, eNOS locus and diabetes 15Discussion
The novelty of our findings lies in searching for the role of
eNOS gene in influencing the platelet phenotype in high
coronary risk diabetic and non-diabetic patients on dual
antiplatelet treatment. We have provided evidence of
a contribution of eNOS gene in affecting platelet aggrega-
tion in ACS non-diabetic patients, possibly reducing NO
availability, and thus conferring a ‘‘hyperaggregable
phenotype’’ to platelets in spite of the dual antiplatelet
therapy. Of interest, the present study shows that the eNOS
4a allele may modulate residual platelet reactivity to AA in
non-diabetic patients, thus suggesting a decreased
response to aspirin therapy in 4a allele carriers. Really,
aspirin highly improves the NO production in platelets, by
increasing eNOS expression, and maximal NO bioavailability
almost doubles after incubation with aspirin [22]. It has
been suggested that the high NO production could coun-
teract the effect of thromboxane and inhibit platelet
activation and aggregation, thus compensating for the
reduction in prostacyclin concentrations by aspirin [22].
Finally, our results show a significantly higher preva-
lence of the eNOS 4a allele in diabetics in comparison to
non-diabetic ACS patients, so confirming data from litera-
ture reporting its role in increasing susceptibility to both
diabetes and its complications [23,24].
Platelet NO appears to play a role in inhibiting recruit-
ment of platelets to the growing thrombus after platelet
activation [4]. NO inhibits platelet aggregation and adhe-
sion via activation of soluble guanylyl cyclase (sGC), which
increases intracellular cGMP levels [25]. Data from anexperimental study performed on collagen-stimulated
rabbit platelets [26] reported that cGMP, the NO effector,
may have an inhibitory effect on collagen-induced aggre-
gation by inhibiting AA release. Moreover, data from an in
vivo study reported that the NO/cGMP pathway may inhibit
the signaling cascade of thromboxane A2 receptor through
phosphorylation by cGMP-dependent protein kinase (cGK),
and through collagen-induced AA release by suppressing
Ca2þ-activated phospholipase A2 activity [27]. Changes in
the activity of platelet eNOS are responsible for abnormal
platelet activation: recent evidence indicates a complex
biphasic interaction between NO and platelet activation
and aggregation; platelet-derived NO may stimulate
platelets [28] through an initial transient stimulatory
response, able to promote platelet aggregation, and
a subsequent inhibitory response that limits the size of
thrombi. Additional evidence indicates that low NO
concentrations promote a platelet degranulation; on the
contrary, high NO concentrations inhibit the exocytosis of
dense granules [29].
NO availability has been related to several poly-
morphisms in the eNOS gene [8e11]. A functional role for
polymorphisms at eNOS locus has been demonstrated:
experimental studies evidenced that eNOS 4a/4b poly-
morphism in the intron 4 of eNOS gene, which represents
a source of 27nt small RNA, is able to inhibit eNOS
expression [30]. eNOS polymorphic variants other than 4a/
4b polymorphism have been described to influence eNOS
activity by different mechanisms. In particular, eNOS
786T > C SNP is reported to affect eNOS gene transcrip-
tion efficiency, thus resulting in a 50% reduction in gene
Table 4 Univariate and multivariate logistic regression analysis for the presence or absence of high residual platelet reactivity
(RPR), according to eNOS polymorphisms, in non-diabetic patients
RPR by AA RPR by Collagen RPR by ADP
OR (95% CI) p OR (95% CI) p OR (95% CI) p
Univariate logistic regression analysis
Dominant Model
eNOS 786C 1.39 (0.97e2.00) 0.08 1.02 (0.68e1.54) 0.9 1.00 (0.65e1.54) 0.9
eNOS 894T 0.92 (0.66e1.27) 0.6 0.81 (0.56e1.18) 0.3 1.10 (0.74e1.64) 0.6
eNOS 4a 1.51 (1.07e2.12) 0.02 1.21 (0.82e1.81) 0.3 1.34 (0.88e2.03) 0.6
Recessive Model
eNOS 786C 0.88 (0.58e1.33) 0.5 1.25 (0.79e1.95) 0.3 0.94 (0.57e1.55) 0.8
eNOS 894T 0.92 (0.57e1.49) 0.7 1.24 (0.73e2.08) 0.4 0.71 (0.38e1.35) 0.3
eNOS 4a 0.49 (0.11e2.18) 0.3 0.35 (0.04e2.69) 0.3 e e
Additive Model
eNOS 786C 1.14 (0.70e1.86) 0.6 1.21 (0.71e2.04) 0.5 0.95 (0.53e1.69) 0.9
eNOS 894T 0.88 (0.53e1.47) 0.6 1.06 (0.61e1.86) 0.8 0.79 (0.39e1.55) 0.5
eNOS 4a 0.56 (0.12e2.52) 0.5 0.38 (0.05e2.91) 0.3 e e
Multivariate logistic regression analysis for eNOS 4a allele (Dominant Model )
eNOS 4a 1.51 (1.02e2.22) 0.04 e e e e
Age 1.03 (1.01e1.04) 0.003 e e e e
Gender 1.11 (0.73e1.69) 0.6 e e e e
Smoking habit 1.19 (0.81e1.73) 0.4 e e e e
Hypertension 1.36 (0.92e2.01) 0.1 e e e e
Ejection fraction 40% 0.71 (0.46e1.08) 0.1 e e e e
Appendix A
Supplemental material
Supplementary information for this manuscript can be
downloaded at doi: 10.1016/j.numecd.2009.07.001.
16 C. Fatini et al.expression [9]. On the contrary, the eNOS 894G > T poly-
morphism has been recently demonstrated not to affect
cellular NO synthesis in vivo [31].
In the present study, we confirmed results from our
previous study [12], showing a similar prevalence of the 4a
rare allele in ACS patients.
Findings from this study showed that eNOS locus modu-
lated platelet aggregability in non-diabetic, but not in
diabetic ACS patients on dual antiplatelet treatment, so
suggesting that eNOS 4a allele could represent a predis-
posing factor for atherothrombotic disease in diabetes via
endothelial dysfunction NO-mediated, rather than through
a modulation of the platelet phenotype, which could play
a major role in ACS non-diabetic patients. Actually, in
diabetes the effect of a genetic predisposition in modu-
lating platelet NO availability is of lesser impact than an
altered glycemic control, which influences platelet func-
tion via several deeply investigated mechanisms [32].
Moreover, the lack of association between eNOS 4a allele
and platelet aggregability in diabetic patients may be also
due to the smaller sample size of the diabetic group.
This study suffers from some limitations: the effect of
antiplatelet therapy, which nevertheless might have
contributed to an underestimation of any true effect; the
lack of a direct measure of platelets eNOS activity in
addition to platelet reactivity, which would more clearly
establish the relationship between eNOS alleles and eNOS
and platelet function; finally, the lack of measurements of
NOX levels, which might allow to evaluate the NO produc-
tion and might contribute to the overall interpretation of
data. Another relevant limitation is the small sample size of
the diabetic group, which might have influenced the results
concerning the lack of association between eNOS 4a allele
and platelet aggregation in response to AA stimulus.In conclusion, our study indicates that eNOS gene, and in
particular 4a allele, may be a determinant of higher platelet
aggregability and residual platelet reactivity in non-diabetic
ACS patients. This finding may allow to recognize a mecha-
nism, other than diabetes, able to induce platelet hyper-
reactivity in high risk patients and to suggest future
pharmacogenetic strategies, such as platelet NO donors and
NO-donating aspirin, able to offer a better control of platelet
function and of endothelial dysfunction.
Finally, ACE-inhibitors therapy has to be considered in
relation to NO availability. Treatment with ACE-inhibitors
may be of interest to restore a physiological activity of
endothelial cells of both diabeteic and non-diabetic patients.
It has been demonstrated in endothelium-denuded dia-
betic aortas [33] that ACE-inhibitors are able to block non-
endothelial NOX activity. Moreover, in diabetes the
production of reactive oxygen species (ROS), further
increased by the eNOS uncoupling ‘‘phenomenom’’,
contributes to the lack of antioxidant role of eNOS.
Accordingly, ACE-inhibitors therapy may improve endothe-
lial function via the novel mechanism of recoupling eNOS.References
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